Growth hormone therapy and risk of malignancy

Endocrinologist

Volumn 18, Issue 1, 2008, Pages 39-43

  Smit, Pauline ^a   Koppeschaar, Hans P F ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Gowth hormone; Malignancy; Tumor

Indexed keywords

GROWTH HORMONE;

ACROMEGALY; BREAST CANCER; CANCER RISK; CARCINOGENESIS; GROWTH HORMONE DEFICIENCY; HUMAN; HYPOPITUITARISM; LARGE INTESTINE CANCER; LONG TERM CARE; NONHUMAN; PROSTATE CANCER; REVIEW; STOMACH CANCER;

EID: 40049095676     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/TEN.0b013e3181652369     Document Type: Review

References (96)

1. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev. 1993;14:20-39.
2. Le Roith D, Bondy C, Yakar S, et al. The somatomedin hypothesis: 2001. Endocr Rev. 2001;22:53-74.
3. Zhu T, Goh EL, Graichen R, et al. Signal transduction via the growth hormone receptor. Cell Signal. 2001;13:599-616.
4. Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990;323:1-6.
5. Perls TT, Reisman NR, Olshansky SJ. Provision or distribution of growth hormone for "antiaging": clinical and legal issues. JAMA. 2005; 294:2086-2090.
6. Cummings DE, Merriam GR. Growth hormone therapy in adults. Annu Rev Med. 2003;54:513-533.
7. Baum HB, Biller BM, Finkelstein JS, et al. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med. 1996;125:883-890.
8. Biller BM, Sesmilo G, Baum HB, et al. Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency. J Clin Endocrinol Metab. 2000;85:970-976.
9. Feldt-Rasmussen U, Wilton P, Jonsson P. Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults. Growth Horm IGF Res. 2004;14(Suppl A):S51-S58.
10. Monson JP. Long-term experience with GH replacement therapy: efficacy and safety. Eur J Endocrinol. 2003;148(Suppl 2):S9-S14.
11. Hertoghe T, Schuder S. Growth hormone for "antiaging." JAMA. 2006; 295:888-890.
12. Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146:104-115.
13. Cohn L, Feller AG, Draper MW, et al. Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentrations. Clin Endocrinol (Oxf). 1993;39: 417-425.
14. Holloway L, Butterfield G, Hintz RL, et al. Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women. J Clin Endocrinol Metab. 1994;79:470-479.
15. Chipman JJ, Attanasio AF, Birkett MA, et al. The safety profile of GH replacement therapy in adults. Clin Endocrinol (Oxf). 1997;46:473-481.
16. Abs R, Bengtsson BA, Hernberg-Stahl E, et al. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin Endocrinol (Oxf). 1999;50: 703-713.
17. Yuen KC, Frystyk J, White DK, et al. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency. Clin Endocrinol (Oxf). 2005;63:428-436.
18. Pepine CJ, Aloia J. Heart muscle disease in acromegaly. Am J Med. 1970;48:530-534.
19. Fazio S, Cittadini A, Biondi B, et al. Cardiovascular effects of short-term growth hormone hypersecretion. J Clin Endocrinol Metab. 2000;85: 179-182.
20. Mercuro G, Zoncu S, Colonna P, et al. Cardiac dysfunction in acromegaly: evidence by pulsed wave tissue Doppler imaging. Eur J Endocrinol. 2000;143:363-369.
21. Alexander L, Appleton D, Hall R, et al. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf). 1980;12:71-79.
22. Bengtsson BA, Eden S, Ernest I, et al. Epidemiology and long-term survival in acromegaly: a study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand. 1988;223:327-335.
23. Holly JM, Gunnell DJ, Davey Smith G. Growth hormone, IGF-I and cancer: less intervention to avoid cancer? More intervention to prevent cancer? J Endocrinol. 1999;162:321-330.
24. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998;351:1393-1396.
25. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998;279: 563-566.
26. Harman SM, Metter EJ, Blackman MR, et al. Serum levels of insulinlike growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostatespecific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab. 2000;85:4258-4265.
27. Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 1999;91:620-625.
28. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr. 2001;131:3109S-3120S.
29. Gibney J, Johannsson G. Long-term monitoring of insulin-like growth factor I in adult growth hormone deficiency: a critical appraisal. Horm Res. 2004;62(Suppl 1):66-72.
30. Moller J, Jorgensen JO, Lauersen T, et al. Growth hormone dose regimens in adult GH deficiency: effects on biochemical growth markers and metabolic parameters. Clin Endocrinol (Oxf). 1993;39:403-408.
31. Isgaard J, Carlsson L, Isaksson OG, et al. Pulsatile intravenous growth hormone (GH) infusion to hypophysectomized rats increases insulin-like growth factor I messenger ribonucleic acid in skeletal tissues more effectively than continuous GH infusion. Endocrinology. 1988;123:2605-2610.
32. Hoffman DM, O'Sullivan AJ, Baxter RC, et al. Diagnosis of growth-hormone deficiency in adults. Lancet. 1994;343:1064-1068.
33. Hartman ML, Crowe BJ, Biller BM, et al. Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab. 2002;87:477-485.
34. Wolthers T, Hoffman DM, Nugent AG, et al. Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women. Am J Physiol Endocrinol Metab. 2001;281:E1191-E1196.
35. Johannsson G, Bjarnason R, Bramnert M, et al. The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age, and gender. J Clin Endocrinol Metab. 1996;81:1575-1581.
36. Drake WM, Coyte D, Camacho-Hubner C, et al. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. J Clin Endocrinol Metab. 1998;83:3913-3919.
37. Bengtsson BA, Abs R, Bennmarker H, et al. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults: KIMS Study Group and the KIMS International Board. J Clin Endocrinol Metab. 1999;84:3929-3935.
38. Gotherstrom G, Svensson J, Koranyi J, et al. A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab. 2001;86:4657-4665.
39. Svensson J, Sunnerhagen KS, Johannsson G. Five years of growth hormone replacement therapy in adults: age- and gender-related changes in isometric and isokinetic muscle strength. J Clin Endocrinol Metab. 2003;88:2061-2069.
40. Yakar S, Liu JL, Fernandez AM, et al. Liver-specific IGF-1 gene deletion leads to muscle insulin insensitivity. Diabetes. 2001;50:1110-1118.
41. Sjogren K, Liu JL, Blad K, et al. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci. 1999;96:7088-7092.
42. Finkelstein JW, Roffwarg HP, Boyar RM, et al. Age-related change in the twenty-four-hour spontaneous secretion of growth hormone. J Clin Endocrinol Metab. 1972;35:665-670.
43. Veldhuis JD, Johnson ML. Cluster analysis: a simple, versatile, and robust algorithm for endocrine pulse detection. Am J Physiol. 1986;250: E486-E493.
44. Jansson JO, Albertsson-Wikland K, Eden S, et al. Effect of frequency of growth hormone administration on longitudinal bone growth and body weight in hypophysectomized rats. Acta Physiol Scand. 1982;114:261-265.
45. Clark RG, Jansson JO, Isaksson O, et al. Intravenous growth hormone: growth responses to patterned infusions in hypophysectomized rats. J Endocrinol. 1985;104:53-61.
46. Jorgensen JO, Moller N, Lauritzen T, et al. Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulin-like growth factor-I and metabolic indices. J Clin Endocrinol Metab. 1990;70:1616-1623.
47. Laursen T, Jorgensen JO, Christiansen JS. Metabolic response to growth hormone (GH) administration in GH-deficient patients: effects on circulating insulin-like growth factor-1 and metabolic indices. Endocrinol Metab. 1994;1:33-40.
48. Tamborlane WV, Genel M, Gianfredi S, et al. The effect of small but sustained elevations in circulating growth hormone on fuel metabolism in growth hormone deficiency. Pediatr Res. 1984;18:212-215.
49. Wright AD, Hill DM, Lowy C, et al. Mortality in acromegaly. Q J Med. 1970;39:1-16.
50. Rajasoorya C, Holdaway IM, Wrightson P, et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf). 1994;41:95-102.
51. Klein I, Parveen G, Gavaler JS, et al. Colonic polyps in patients with acromegaly. Ann Intern Med. 1982;97:27-30.
52. Pines A, Rozen P, Ron E, et al. Gastrointestinal tumors in acromegalic patients. Am J Gastroenterol. 1985;80:266-269.
53. Ron E, Gridley G, Hrubec Z, et al. Acromegaly and gastrointestinal cancer. Cancer. 1991;68:1673-1677.
54. Ezzat S, Melmed S. Clinical review 18: are patients with acromegaly at increased risk for neoplasia? J Clin Endocrinol Metab. 1991;72:245-249.
55. Jenkins PJ, Besser M. Clinical perspective: acromegaly and cancer - a problem. J Clin Endocrinol Metab. 2001;86:2935-2941.
56. Turner HE, Wass JA. Modern approaches to treating acromegaly. Q J Med. 2000;93:1-6.
57. Jenkins PJ. Cancers associated with acromegaly. Neuroendocrinology. 2006;83:218-223.
58. Present D, Bertoni F, Enneking WF. Osteosarcoma of the mandible arising in fibrous dysplasia: a case report. Clin Orthop Relat Res. 1986;204:238-244.
59. Mortensen A, Bojsen-Moller M, Rasmussen P. Fibrous dysplasia of the skull with acromegaly and sarcomatous transformation: two cases with a review of the literature. J Neurooncol. 1989;7:25-29.
60. Lima GA, Gomes EM, Nunes RC, et al. Osteosarcoma and acromegaly: a case report and review of the literature. J Endocrinol Invest. 2006;29:1006-1011.
61. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 1990;336:285-288.
62. Svensson J, Bengtsson B, Rosen T, et al. The incidence of malignant disease and cardiovascular morbidity in hypopituitary patients with or without growth hormone replacement therapy. J Clin Endocrinol Metab. 2004;89:3306-3312.
63. Tornell J, Carlsson B, Pohjanen P, et al. High frequency of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice created from two different strains of mice. J Steroid Biochem Mol Biol. 1992;43:237-242.
64. Emerman JT, Leahy M, Gout PW, et al. Elevated growth hormone levels in sera from breast cancer patients. Horm Metab Res. 1985;17:421-424.
65. Triantafillidis JK, Merikas E, Govosdis V, et al. Increased fasting serum levels of growth hormone and gastrin in patients with gastric and large bowel cancer. Hepatogastroenterology. 2003;50(Suppl 2):cclvi-cclx
66. Mazzoccoli G, Giuliani A, Bianco G, et al. Decreased serum levels of insulin-like growth factor (IGF)-I in patients with lung cancer: temporal relationship with growth hormone (GH) levels. Anticancer Res. 1999;19:1397-1399.
67. Yakar S, Leroith D, Brodt P. The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: lessons from animal models. Cytokine Growth Factor Rev. 2005;16:407-420.
68. Laban C, Bustin SA, Jenkins PJ. The GH-IGF-I axis and breast cancer. Trends Endocrinol Metab. 2003;14:28-34.
69. Khandwala HM, McCutcheon IE, Flyvbjerg A, et al. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev. 2000;21:215-244.
70. Love RR, Rose DR, Surawicz TS, et al. Prolactin and growth hormone levels in premenopausal women with breast cancer and healthy women with a strong family history of breast cancer. Cancer. 1991;68:1401-1405.
71. Fuhrman B, Barba M, Schunemann HJ, et al. Basal growth hormone concentrations in blood and the risk for prostate cancer: a case-control study. Prostate. 2005;64:109-115.
72. Wagner K, Hemminki K, Israelsson E, et al. Association of polymorphisms and haplotypes in the human growth hormone 1 (GH1) gene with breast cancer. Endocr Relat Cancer. 2005;12:917-928.
73. Horan M, Millar DS, Hedderich J, et al. Human growth hormone 1 (GH1) gene expression: complex haplotype-dependent influence of polymorphic variation in the proximal promoter and locus control region. Hum Mutat. 2003;21:408-423.
74. Le Marchand L, Donlon T, Seifried A, et al. Association of a common polymorphism in the human GH1 gene with colorectal neoplasia. J Natl Cancer Inst. 2002;94:454-460.
75. Ren Z, Cai Q, Shu XO, et al. Genetic polymorphisms in the human growth hormone-1 gene (GH1) and the risk of breast carcinoma. Cancer. 2004;101:251-257.
76. Wagner K, Hemminki K, Grzybowska E, et al. Polymorphisms in the growth hormone receptor: a case-control study in breast cancer. Int J Cancer. 2006;118:2903-2906.
77. Rudd MF, Webb EL, Matakidou A, et al. Variants in the GH-IGF axis confer susceptibility to lung cancer. Genome Res. 2006;16:693-701.
78. Canzian F, McKay JD, Cleveland RJ, et al. Genetic variation in the growth hormone synthesis pathway in relation to circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3, and breast cancer risk: results from the European prospective investigation into cancer and nutrition study. Cancer Epidemiol Biomarkers Prev. 2005;14:2316-2325.
79. Wagner K, Hemminki K, Grzybowska E, et al. Polymorphisms in genes involved in GH1 release and their association with breast cancer risk. Carcinogenesis. 2006;27:1867-1875.
80. Rapaport R, Oberfield SE, Robison L, et al. Relationship of growth hormone deficiency and leukemia. J Pediatr. 1995;126:759-761.
81. Allen DB, Rundle AC, Graves DA, et al. Risk of leukemia in children treated with human growth hormone: review and reanalysis. J Pediatr. 1997;131:S32-S36.
82. Watanabe S, Tsuenematsu Y, Fujimoto J, et al. Leukemia in patients treated with growth hormone. Lancet. 1988;1(8595):1159-1160.
83. Nishi Y, Tanaka T, Takano K, et al. Recent status in the occurrence of leukemia in growth hormone-treated patients in Japan: GH Treatment Study Committee of the Foundation for Growth Science, Japan. J Clin Endocrinol Metab. 1999;84:1961-1965.
84. Swerdlow AJ, Higgins CD, Adlard P, et al. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet. 2002;360:273-277.
85. Wilton P, Mattsson A, Abs R, et al. Neoplasms reported during growth hormone replacement in KIMS. Presented at: The Endocrine Society's 85th Annual Meeting; June 20, 2003; Philadelphia, PA. Abstract OR20-6.
86. Popovic V, Damjanovic S, Micic D, et al. Increased incidence of neoplasia in patients with pituitary adenomas: the Pituitary Study Group. Clin Endocrinol (Oxf). 1998;49:441-445.
87. Nilsson B, Gustavasson-Kadaka E, Bengtsson BA, et al. Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality. J Clin Endocrinol Metab. 2000;85:1420-1425.
88. Swerdlow AJ, Reddingius RE, Higgins CD, et al. Growth hormone treatment of children with brain tumors and risk of tumor recurrence. J Clin Endocrinol Metab. 2000;85:4444-4449.
89. Packer RJ, Boyett JM, Janss AJ, et al. Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control. J Clin Oncol. 2001;19:480-487.
90. Sklar CA, Mertens AC, Mitby P, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2002;87:3136-3141.
91. Leung W, Rose SR, Zhou Y, et al. Outcomes of growth hormone replacement therapy in survivors of childhood acute lymphoblastic leukemia. J Clin Oncol. 2002;20:2959-2964.
92. Frajese G, Drake WM, Loureiro RA, et al. Hypothalamo-pituitary surveillance imaging in hypopituitary patients receiving long-term GH replacement therapy. J Clin Endocrinol Metab. 2001;86:5172-5175.
93. Hatrick AG, Boghalo P, Bingham JB, et al. Does GH replacement therapy in adult GH-deficient patients result in recurrence or increase in size of pituitary tumours? Eur J Endocrinol. 2002;146:807-811.
94. Attanasio AF, Lamberts SW, Matranga AM, et al. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment: Adult Growth Hormone Deficiency Study Group. J Clin Endocrinol Metab. 1997;82:82-88.
95. Cuneo RC, Judd S, Wallace JD, et al. The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults. J Clin Endocrinol Metab. 1998;83:107-116.
96. Bhatia S, Sklar C. Second cancers in survivors of childhood cancer. Nat Rev Cancer. 2002;2:124-132.